Professional
Added to YB: 2025-03-24
Pitch date: 2025-01-07
NVO [bullish]
Novo Nordisk A/S
-41.6%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 83.83
Price Target
N/A
Dividend
3.63%
EV/EBITDA
8.96
P/E
13.76
EV/Sales
4.74
Sector
Pharmaceuticals
Category
growth
Burke Wealth Management Portfolio Holding: Novo Nordisk A/S
NVO (holding update): Shares down on RFK Jr. HHS nomination & Cagri-Sema Phase III results (22.7% weight loss vs 25% target). Still in-line with Zepbound (20%) & better than Wegovy (15%). Obesity market potential huge, supply-constrained. Overreaction to results; Novo remains strong contender in growing GLP-1 market.
Read full article (2 min)